Prostatilen
Research OnlyA peptide complex extracted from bovine prostate glands, developed in Russia and registered as a pharmaceutical for prostatitis treatment. Available as suppositories and injections in Russia and CIS countries. Has more clinical documentation than most bioregulators but lacks Western validation.
Prostate peptide extract · Samprost · Vitaprost · Prostate cytamins
8 human studies
- Preclinical
- 39%
- Human research
- 44%
Based on 18 cited sources
Numeric assessment unreviewed
A historical numeric score is recorded but has not passed a current, compound-specific assessment review. No numeric score is displayed.
This is a limitation of the numeric assessment, not a measured absence of benefit. It does not re-review the separately recorded catalogue classification or establish efficacy or safety.
The proposed mechanisms of Prostatilen are based primarily on Russian clinical and preclinical research. As a peptide complex rather than a single defined molecule, mechanisms are attributed to the collective action of multiple prostate-derived peptide fractions.
How It Works (Simplified)
Prostatilen targets prostate health through multiple proposed pathways:
Modulates inflammatory cytokines in prostate tissue, reducing chronic inflammation associated with prostatitis and BPH.
Improves blood flow to prostate tissue, potentially enhancing nutrient delivery and waste removal from the gland.
Affects smooth muscle tone in the prostate and lower urinary tract, potentially improving urinary flow and reducing symptoms.
Modulates local immune responses in prostate tissue, potentially normalizing immune-mediated inflammation.
Key Context: Prostatilen operates on the Russian “bioregulation” theory that tissue-specific peptides from one organism can support equivalent tissues in another. This theoretical framework has not been validated by Western biomedical research.
Important Limitations
- Not a defined molecule: Cannot characterize pharmacokinetics, binding sites, or precise mechanisms
- Bovine tissue source: Quality depends entirely on manufacturing standards and animal sourcing
- Russian research only: No independent Western validation of claimed mechanisms
- Translation uncertainty: Proposed mechanisms extrapolated from clinical outcomes, not molecular studies
- Standardization challenges: Peptide content may vary between batches
- Theoretical framework: “Bioregulation” theory not accepted in Western medicine
Comparison to Defined Peptides
Unlike synthetic peptides such as BPC-157, epithalon, or selank, Prostatilen:
| Aspect | Prostatilen | Synthetic Peptides |
|---|---|---|
| Composition | Variable mixture | Defined sequence |
| Quality control | Difficult | Straightforward |
| Mechanism study | Limited | Can be characterized |
| Batch consistency | Variable | Consistent |
| Regulatory path | Complex (biologics) | Clearer |
This distinction is critical when evaluating evidence and making comparisons to other peptides in the bioregulator field.
Based on Russian clinical protocols: Initial effects on inflammation markers may begin. Suppository formulations provide direct prostatic absorption. Some patients report early symptom relief.
PMID:1823682Continued anti-inflammatory effects. Russian studies typically report measurable improvements in urinary symptom and obstruction scores within weeks. Microcirculation effects developing.
PMID:17315707Standard Russian treatment course is 5-10 days for suppositories, with repeat courses. Most clinical improvements reported within this timeframe. Sustained use shows cumulative benefits in Russian data.
PMID:2058122Maintenance protocols in Russia involve periodic repeat courses. Long-term efficacy and safety data limited. Some Russian studies followed patients for 6-12 months with repeat treatments.
Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Thymalin
CompatibleBoth Russian bioregulator peptide complexes from the same research tradition. Thymalin targets immune modulation via thymus, Prostatilen targets prostate tissue. Often used together in Russian protocols.
Epithalon
CompatibleDifferent targets within Russian bioregulation framework - epithalon for cellular longevity via telomerase, Prostatilen for prostate-specific tissue support.
BPC-157
CompatibleDifferent regenerative mechanisms - BPC-157 for systemic tissue healing via growth factor modulation, Prostatilen for prostate-specific tissue support.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Use the source links in the research discussion above to inspect the referenced records.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength labels summarize the cited material for this entry and should be read alongside its population, model, and study limitations.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Prostatilen
Related Peptides
CJC-1295
DAC:GRF · Modified GRF 1-29 · Tetrasubstituted GRF
A synthetic analog of growth hormone-releasing hormone (GHRH) with extended half-life. Limited clinical development; not approved for any indication.
Follistatin
FST · FS-344 · FS-315 +1
Follistatin is an endogenous protein that binds activin and myostatin. Small human AAV gene-transfer studies and trials of an engineered follistatin-based protein do not establish clinical benefit or safety for native follistatin protein administration.
GHRP-2
Growth Hormone Releasing Peptide-2 · Pralmorelin · KP-102
A synthetic hexapeptide GH secretagogue with the strongest GH-releasing potency in its class. More potent than GHRP-6 with different side effect profile: less appetite stimulation but greater cortisol and prolactin elevation. Approved in Japan as Pralmorelin for GH deficiency diagnosis. Extensively studied in human pharmacology with robust clinical data.
GHRP-6
Growth Hormone Releasing Peptide-6 · SKF-110679 · Growth Hormone-Releasing Hexapeptide
A first-generation growth hormone secretagogue that stimulates GH release through the ghrelin receptor. Less selective than newer alternatives with effects on cortisol and prolactin. Historically significant as the peptide that led to ghrelin discovery. Cuban CIGB leads global cytoprotective research. Not approved for any indication.
Human Chorionic Gonadotropin (hCG)
hCG · Choriogonadotropin · Pregnyl +5
A glycoprotein hormone FDA-approved for ovulation induction, cryptorchidism, and hypogonadotropic hypogonadism. Functions as an LH receptor agonist with over 50 years of clinical use in reproductive medicine. Gold standard trigger for assisted reproductive technology.
Hexarelin
Examorelin · HEX · Growth Hormone Releasing Hexapeptide +2
The most potent synthetic GHRP (Growth Hormone Releasing Peptide), a hexapeptide that strongly stimulates GH release via the ghrelin receptor. Notable for cardioprotective effects independent of GH release. Development discontinued due to rapid desensitization with repeated dosing. Italian research leads global investigation.
Compared With
3 comparisonsConditions Studied
3 entries- Prostatilen for Chronic Prostatitis Prostatilen is registered in Russia specifically for chronic prostatitis treatment. Multiple Russian clinical studies report reduc…
- Prostatilen for Benign Prostatic Hyperplasia (BPH) Russian clinical studies report improvements in IPSS scores, peak flow rates, and quality of life measures in BPH patients. Prosta…
- Prostatilen for Male Reproductive Health Some Russian research suggests Prostatilen may support overall prostate health and male reproductive function. Claims include impr…